低氧及氧化应激对脂肪细胞分泌因子表达的调节及其机制的研究
|
摘要
肥胖与胰岛素抵抗、Ⅱ型糖尿病及心血管疾病(cardiovascular
disease，CVD)的发生有密切的关系。脂肪组织可以产生多种具有生物活性的物质，称为脂肪细胞分泌因子(adipokines，ADS)。ADS参与到机体的能量代谢、炎症反应及心血管功能等病理生理过程中。肥胖时ADS的异常调节，尤其是脂联素(adiponectin，AD)、纤溶酶原激活物抑制剂-1(plasminogen activator inhibitor 1，PAI-1)及白介素6(interleukin-6，IL-6)的异常，是导致肥胖相关的胰岛素抵抗及CVD发生的重要原因。最近研究发现，肥胖可以导致机体及脂肪组织内出现氧化应激(oxidative stress，OS)。很多证据都说明，随着脂肪的快速增长，可能引起脂肪组织局部的相对低氧。这种低氧及OS对ADS表达的影响及其在肥胖相关疾病中的作用并不清楚。因此，本实验研究了低氧及OS对三种重要的ADS(AD、PAI-1及IL-6)在脂肪细胞中的调节，并探讨其可能的机制。
1 目的
(1)研究低氧对AD及PAI-1表达的调节，并对其机制进行探讨。
(2)研究OS对AD、PAI-1及IL-6表达的调节，并对其机制进行
Obesity is causally associated with the development of insulin resistance, type II diabetes and cardiovascular diseases (CVD). Adipose tissue is now recognized to be an important endocrine organ, secreting a variety of bioactive factors, named adipokines, which are involved in energy metabolism, inflammatory response and cardiovascular functions. Aberrant production of adipose-derived adipokines, especially adiponectin (AD), plasminogen activator inhibitor 1 (PAI-1) and interleukin-6 (IL-6), is now believed to play a causative role in the development of obesity-associated insulin resistance and cardiovascular disorders. Previous study suggests that obesity may induce systemic oxidative stress (OS) and the increase of reactive oxygen species (ROS) in accumulated fat. Accumulating evidences highlight the notion that hypoxia may exist in fat depots as the fat mass increases. It is not very clear what roles the local hypoxia and OS play in the pathogenesis of obesity and obesity-related diseases. In this study, we investigated the effects of hypoxia and OS on production of three key ADS (AD, PAI-1 and IL-6), and explored the
disease，CVD)的发生有密切的关系。脂肪组织可以产生多种具有生物活性的物质，称为脂肪细胞分泌因子(adipokines，ADS)。ADS参与到机体的能量代谢、炎症反应及心血管功能等病理生理过程中。肥胖时ADS的异常调节，尤其是脂联素(adiponectin，AD)、纤溶酶原激活物抑制剂-1(plasminogen activator inhibitor 1，PAI-1)及白介素6(interleukin-6，IL-6)的异常，是导致肥胖相关的胰岛素抵抗及CVD发生的重要原因。最近研究发现，肥胖可以导致机体及脂肪组织内出现氧化应激(oxidative stress，OS)。很多证据都说明，随着脂肪的快速增长，可能引起脂肪组织局部的相对低氧。这种低氧及OS对ADS表达的影响及其在肥胖相关疾病中的作用并不清楚。因此，本实验研究了低氧及OS对三种重要的ADS(AD、PAI-1及IL-6)在脂肪细胞中的调节，并探讨其可能的机制。
1 目的
(1)研究低氧对AD及PAI-1表达的调节，并对其机制进行探讨。
(2)研究OS对AD、PAI-1及IL-6表达的调节，并对其机制进行
Obesity is causally associated with the development of insulin resistance, type II diabetes and cardiovascular diseases (CVD). Adipose tissue is now recognized to be an important endocrine organ, secreting a variety of bioactive factors, named adipokines, which are involved in energy metabolism, inflammatory response and cardiovascular functions. Aberrant production of adipose-derived adipokines, especially adiponectin (AD), plasminogen activator inhibitor 1 (PAI-1) and interleukin-6 (IL-6), is now believed to play a causative role in the development of obesity-associated insulin resistance and cardiovascular disorders. Previous study suggests that obesity may induce systemic oxidative stress (OS) and the increase of reactive oxygen species (ROS) in accumulated fat. Accumulating evidences highlight the notion that hypoxia may exist in fat depots as the fat mass increases. It is not very clear what roles the local hypoxia and OS play in the pathogenesis of obesity and obesity-related diseases. In this study, we investigated the effects of hypoxia and OS on production of three key ADS (AD, PAI-1 and IL-6), and explored the
引文
[1] Norgan NG. Population differences in body composition in relation to the body mass index. Eur J Clin Nutr. 1994; 48(Suppl 3): S10-25; discussion S26-7.
[2] Gallagher D, Visser M, Sepulveda D, Pierson RN, Harris T, Heymsfield SB. How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am J Epidemiol. 1996; 143(3): 228-39.
[3] Kopelman PG Obesity as a medical problem. Nature. 2000; 404(6778): 635-43.
[4] WHO. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Consultation. World Health Organ Tech Rep Ser. 1995; 854: 1-452.
[5] WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363(9403): 157-63.
[6] Eckel RH, York DA, Rossner S, Hubbard V, Caterson I, St Jeor ST, Hayman LL, Mullis RM, Blair SN. American Heart Association. Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: executive summary. Circulation. 2004; 110(18): 2968-75.
[7] Seidell JC. Prevalence and time trends of obesity in Europe. J Endocrinol Invest. 2002; 25(10): 816-22.
[8] Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA. 2004; 291 (23): 2847-50.
[9] Li G, Chen X, Jang Y, Wang J, Xing X, Yang W, Hu Y. Obesity, coronary heart disease risk factors and diabetes in Chinese: an approach to the criteria of obesity in the Chinese population. Obes Rev. 2002; 3(3): 167-72.
[10] Schwarzenberg SJ. Obesity in children: epidemic and opportunity. Minn Med. 2005; 88(9): 62-6.
[11] Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, Grummer-Strawn LM, Curtin LR, Roche AF, Johnson CL. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics. 2002; 109(1): 45-60.
[12] Magarey AM, Daniels LA, Boulton TJ. Prevalence of overweight and obesity in Australian children and adolescents: reassessment of 1985 and 1995 data against new standard international definitions. Med J Aust. 2001; 174(11): 561-4.
[13] Lobstein T, Baur L, Uauy R. IASO International Obesity TaskForce. Obesity in children and young people: a crisis in public health. Obes Rev. 2004;5(Suppl 1): 4-104.
[14] James PT, Leach R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. Obes Res. 2001; 9(Suppl 4): 228S-233S.
[15] Kohn M, Booth M. The worldwide epidemic of obesity in adolescents. Adolesc Med. 2003; 14(1): 1-9.
[16] Krassas GE, Tzotzas T. Do obese children become obese adults: childhood predictors of adult disease. Pediatr Endocrinol Rev. 2004; 1( Suppl 3): 455-9.
[17] Haslam DW, James WP. Obesity. Lancet. 2005; 366(9492): 1197-209.
[18] James WPT, Jackson-Leach R, Ni Mhurchu C. Overweight and obesity (high body mass index). In: Ezzati M, Lopez AD, Rodgers A, Murray CJL, eds. Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors, vol 1. Geneva: WHO, 2004: 497-596.
[19] Strohl KP, Strobel RJ, Parisi RA. Obesity and pulmonary function. In: Bray GA, Bouchard C, James WP, eds. Handbook of obesity: etiology and pathophysiology. 2nd. New York, Marcel Dekker; 2004: 725-739.
[20] Felson DT, Anderson JJ, Naimark A, Walker AM, Meenan RF. Obesity and knee osteoarthritis. The Framingham Study. Ann Intern Med. 1988; 109(1): 18-24.
[21] Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994; 17(9): 961-9.
[22] Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995; 122(7): 481-6.
[23] Seidell JC, Verschuren WM, van Leer EM, Kromhout D. Overweight, underweight, and mortality. A prospective study of 48, 287 men and women. Arch Intern Med. 1996; 156(9): 958-63.
[24] Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH. American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006; 113(6): 898-918.
[25] Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patients. Gastroenterology. 2000; 118(6): 1117-23.
[26] Ko CW, Lee SP. Dietary carbohydrates and gallstones: is there a link? Gastroenterology. 2005; 129(1): 373-5.
[27] Lew EA. Mortality and weight: insured lives and the American Cancer Society studies. Ann Intern Med. 1985; 103(6 (Pt 2)): 1024-9.
[28] Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE. Body weight and mortality among women. N Engl J Med. 1995; 333(11): 677-85.
[29] Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. JAMA. 2003; 289(2): 187-93.
[30] Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J, Hayflick L, Butler RN, Allison DB, Ludwig DS. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005; 352(11): 1138-45.
[31] Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, AI Mamun A, Bonneux L. NEDCOM, the Netherlands Epidemiology and Demography Compression of Morbidity Research Group. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med. 2003; 138(1): 24-32.
[32] Hu FB, Willett WC, Li T, Stampfer MJ, Colditz GA, Manson JE. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med. 2004; 351(26): 2694-703.
[33] Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983; 67(5): 968-77.
[34] Eckei RH. Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1997; 96(9): 3248-50.
[35] Willett WC, Manson JE, Stampfer MJ, Colditz GA, Rosner B, Speizer FE, Hennekens CH. Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range. JAMA. 1995; 273(6): 461-5.
[36] Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, Willett WC. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol. 1995; 141 (12): 1117-27.
[37] Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci. 2001; 321(4): 225-36.
[38] Kasper EK, Hruban RH, Baughman KL. Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. Am J Cardiol. 1992; 70(9): 921-4.
[39] Mattsson E, Larsson UE, Rossner S. Is walking for exercise too exhausting for obese women? Int J Obes Relat Metab Disord. 1997; 21(5): 380-6.
[40] Poirier P, Despres JP. Exercise in weight management of obesity. Cardiol Ciin. 2001; 19(3): 459-70.
[41] Messerli FH. Cardiopathy of obesity-a not-so-Victorian disease. N Engl J Med. 1986; 314(6): 378-80.
[42] Ku CS, Lin SL, Wang DJ, Chang SK, Lee WJ. Left ventricular filling in young normotensive obese adults. Am J Cardiol. 1994; 73(8): 613-5.
[43] Alpert MA, Lambert CR, Panayiotou H, Terry BE, Cohen MV, Massey CV, Hashimi MW, Mukerji V. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. Am J Cardiol. 1995; 76(16): 1194-7.
[44] Cheyne J. A case of apoplexy in which the fleshy part of the heart wasconverted into fat. Dublin Hosp Rep. 1818; 2: 216-223.
[45] Smith HL, Willius FA. Adiposity of the heart: a clinical and pathologic study of one hundred and thirty-six obese patients. Arch Intern Med. 1933; 52: 911-931.
[46] Roberts WC, Roberts JD. The floating heart or the heart too fat to sink: analysis of 55 necropsy patients. Am J Cardiol. 1983; 52(10): 1286-9.
[47] Carpenter HM. Myocardial fat infiltration. Am Heart J. 1962;63:491-6.
[48] Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A. 2000; 97(4): 1784-9.
[49] Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS. Obesity and the risk of heart failure. N Engl J Med. 2002; 347(5): 305-13.
[50] Klein S, Burke LE, Bray GA, Blair S, Allison DB, Pi-Sunyer X, Hong Y, Eckel RH. American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2004; 110(18): 2952-67.
[51] Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med. 2002; 162(10): 1182-9.
[52] McGill HC Jr, McMahan CA, Herderick EE, Zieske AW, Malcom GT, Tracy RE, Strong JP. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation. 2002; 105(23): 2712-8.
[53] Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. A prospective study of risk factors for pulmonary embolism in women. JAMA. 1997; 277(8): 642-5.
[54] Blaszyk H, Wollan PC, Witkiewicz AK, Bjornsson J. Death from pulmonary thromboembolism in severe obesity: lack of association with established genetic and clinical risk factors. Virchows Arch. 1999; 434(6): 529-32.
[55] Blaszyk H, Bjornsson J. Factor V leiden and morbid obesity in fatal postoperative pulmonary embolism. Arch Surg. 2000; 135(12): 1410-3.
[56] Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA. 1978; 240(15): 1607-10.
[57] Arcaro G, Zamboni M, Rossi L, Turcato E, Covi G, Armellini F, Bosello O, Lechi A. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity, Int J Obes RelatMetab Disord. 1999; 23(9): 936-42.
[58] Lee KU. Oxidative stress markers in Korean subjects with insulin resistance syndrome. Diabetes Res Clin Pract. 2001; 54(Suppl 2): S29-33.
[59] Amin RS, Kimball TR, Bean JA, Jeffries JL, Willging JP, Cotton RT, Witt SA, Glascock BJ, Daniels SR. Left ventricular hypertrophy and abnormal ventricular geometry in children and adolescents with obstructive sleep apnea. Am J Respir Crit Care Med. 2002; 165(10): 1395-9.
[60] Brown DL. Sleep disorders and stroke. Semin Neurol. 2006; 26(1): 117-22.
[61] Dursunoglu N, Dursunoglu D. Obstructive sleep apnea syndrome, endothelial dysfunction and coronary atherosclerosis. Tuberk Toraks. 2005; 53(3): 299-306.
[62] Hale CS. Obstructive sleep apnea and cardiovascular disease and mortality: the argument for causality. J Insur Med. 2005; 37(4): 272-82.
[63] Guerra S, Sherrill DL, Bobadilla A, Martinez FD, Barbee RA. The relation of body mass index to asthma, chronic bronchitis, and emphysema. Chest. 2002; 122(4): 1256-63.
[64] Gennuso J, Epstein LH, Paluch RA, Cerny F. The relationship between asthma and obesity in urban minority children and adolescents. Arch Pediatr Adolesc Med. 1998; 152(12): 1197-200.
[65] Schachter LM, Salome CM, Peat JK, Woolcock AJ. Obesity is a risk for asthma and wheeze but not airway hyperresponsiveness. Thorax. 2001; 56(1): 4-8.
[66] Schachter LM, Peat JK, Salome CM. Asthma and atopy in overweight children. Thorax. 2003; 58(12): 1031-5.
[67] Bibi H, Shoseyov D, Feigenbaum D, Genis M, Friger M, Peled R, Sharff S. The relationship between asthma and obesity in children: is it real or a case of over diagnosis? J Asthma. 2004; 41(4): 403-10.
[68] Sims EA, Danforth E Jr, Horton ES, Bray GA, Glennon JA, Salans LB. Endocrine and metabolic effects of experimental obesity in man. Recent Prog Horm Res. 1973; 29: 457-96.
[69] Bray GA. Risks of obesity. Endocrinol Metab Clin North Am. 2003; 32(4): 787-804.
[70] Stevens J, Couper D, Pankow J, Folsom AR, Duncan BB, Nieto FJ, Jones D, Tyroler HA. Sensitivity and specificity of anthropometrics for the prediction of diabetes in a biracial cohort. Obes Res. 2001; 9(11): 696-705.
[71] Pinhas-Hamiel O, Dolan LM, Daniels SR, Standiford D, Khoury PR, Zeitler P. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J Pediatr. 1996; 128(5 Pt 1): 608-15.
[72] Pinkney JH, Sjostrom CD, Gale EA. Should surgeons treat diabetes in severely obese people? Lancet. 2001; 357(9265): 1357-9.
[73] Golay A, Ybarra J. Link between obesity and type 2 diabetes. Best Pract Res Clin Endocrinol Metab. 2005; 19(4): 649-63.
[74] Tilg H, Kaser A. Treatment strategies in nonalcoholic fatty liver disease. Nat Clin Pratt Gastroenterol Hepatol. 2005; 2(3): 148-55.
[75] Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol. 2005; 16(4): 421-7.
[76] Santoliquido A, Di Campli C, Miele L, Gabrieli ML, Forgione A, Zocco MA, Lupascu A, Di Giorgio A, Flore R, Pola P, Gasbarrini G, Gasbarrini A, Tondi P, Grieco A. Hepatic steatosis and vascular disease. Eur Rev Med Pharmacol Sci. 2005; 9(5): 269-71.
[77] Marra F, Aleffi S, Bertolani C, Petrai I, Vizzutti F. Adipokines and liver fibrosis. Eur Rev Med Pharmacol Sci. 2005 Sep-Oct; 9(5): 279-84.
[78] Clark JM, Brancati FL, Diehi AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002; 122(6): 1649-57.
[79] Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology. 2002; 35(4): 746-52.
[80] Wieckowska A, Feldstein AE. Nonalcoholic fatty liver disease in the pediatric population: a review. Curr Opin Pediatr. 2005; 17(5): 636-41.
[81] Clark JM. Weight loss as a treatment for nonalcoholic Fatty liver disease. J Clin Gastroenterol. 2006; 40(Suppl 1): S39-43.
[82] Bugianesi E. Review article: steatosis, the metabolic syndrome and cancer. Aliment Pharmacol Ther. 2005; (22 Suppl 2): 40-3.
[83] Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J, Albanes D. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA. 2005; 294(22): 2872-8.
[84] Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005; 143(3): 199-211.
[85] Hou L, Ji BT, Blair A, Dai Q, Gao YT, Potter JD, Chow WH. Body mass index and colon cancer risk in Chinese people: menopause as an effect modifier. Eur J Cancer. 2006; 42(1): 84-90.
[86] Frezza EE, Wachtel MS, Chiriva-Internati M. Influence of obesity on the risk of developing colon cancer. Gut. 2006; 55(2): 285-91.
[87] Fairfield KM, Willett WC, Rosner BA, Manson JE, Speizer FE, Hankinson SE. Obesity, weight gain, and ovarian cancer. Obstet Gynecol. 2002; 100(2): 288-96.
[88] Sonne-Holm S, Jacobsen S. Osteoarthritis and obesity. Ugeskr Laeger. 2006; 168(2): 187-90.
[89] Leveille SG, Wee CC, Iezzoni LI. Trends in obesity and arthritis among baby boomers and their predecessors, 1971-2002. Am J Public Health. 2005; 95(9): 1607-13.
[90] Gross AF, Fickert S, Gunther KP. Obesity and arthritis. Orthopade. 2005; 34(7): 638-44.
[91] Christensen R, Stigsgaard L, Astrup AV, Bliddal H. Weight loss as therapy of knee osteoarthritis in obese patients-secondary publication. Ugeskr Laeger. 2005; 167(23): 2522-6.
[92] Messier SP, Gutekunst DJ, Davis C, DeVita P. Weight loss reducesknee-joint loads in overweight and obese older adults with knee osteoarthritis. Arthritis Rheum. 2005; 52(7): 2026-32.
[93] Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med. 2003; 163(13): 1524-8.
[94] de Leeuw FE, van der Flier WM, Scheltens P. A 24-year follow-up of body mass index and cerebral atrophy. Neurology. 2005; 64(11): 1990-1;
[95] Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004; 3(3): 169-78.
[96] Green BB, Weiss NS, Daling JR. Risk of ovulatory infertility in relation to body weight. Fertii Steril. 1988; 50(5): 721-6.
[97] Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D'Andrea F, D'Armiento M, Giugliano D. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004; 291(24): 2978-84.
[98] Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2004; 89(6): 2595-600.
[99] Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005; 115(5): 911-9.
[100] Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes Metab. 2004; 30(1): 13-9.
[101] Trujillo ME, Scherer PE. Adiponectin--journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005; 257(2): 167-75.
[102] Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, Matsuzawa Y. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes. 2001; 50(5): 1126-33.
[103] Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 2002; 360(9326): 57-8.
[104] Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H, Kumada M, Ohashi K, Okamoto Y, Nishizawa H, Kishida K, Maeda N, Nagasawa A, Kobayashi H, Hiraoka H, Komai N, Kaibe M, Rakugi H, Ogihara T, Matsuzawa Y. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension. 2003; 42(3): 231-4.
[105] Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, Hokanson JE, Ehrlich J, Eckel RH, Rewers M. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation. 2005; 111(6): 747-53.
[106] Lam KS, Xu A. Adiponectin: protection of the endothelium. Curt Diab Rep. 2005; 5(4): 254-9.
[107] Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M,Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002; 8(7): 731-7.
[108] Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, Yano W, Froguel P, Nagai R, Kimura S, Kadowaki T, Noda T. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem. 2002; 277(29): 25863-6.
[109] Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR, Kumada M, Sato K, Schiekofer S, Ohashi K, Funahashi T, Colucci WS, Walsh K. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med. 2004; 10(12): 1384-9.
[110] Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, Ohashi K, Sakai N, Shimomura I, Kobayashi H, Terasaka N, Inaba T, Funahashi T, Matsuzawa Y. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2002; 106(22): 2767-70.
[111] Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003; 112(1): 91-100.
[112] Tsao TS, Lodish HF, Fruebis J. ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol. 2002; 440(2-3): 213-21.
[113] Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002; 13(2): 84-9.
[114] Patel C, Wyne KL, MeGuire DK. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? Diab Vase Dis Res. 2005; 2(2): 61-6.
[115] Hetzel J, Balletshofer B, Rittig K, Walcher D, Kratzer W, Hombaeh V, Haring HU, Koenig W, Marx N. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vase Biol. 2005; 25(9): 1804-9.
[116] Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002; 8(11): 1288-95.
[117] Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang Cc C, Itani SI, Lodish HF, Ruderman NB. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A. 2002; 99(25): 16309-13.
[118] Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest. 2001; 108(12): 1875-81.
[119] Wu X, Motoshima H, Mahadev K, Stalker TJ, Scalia R, Goldstein BJ. Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes. 2003; 52(6): 1355-63.
[120] Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000; 102(11): 1296-301.
[121] Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999; 100(25): 2473-6.
[122] Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, Kumada M, Hotta K, Nishida M, Takahashi M, Nakamura T, Shimomura I, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation. 2002; 105(24): 2893-8.
[123] Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K, Maeda K, Nagaretani H, Kishida K, Maeda N, Nagasawa A, Funahashi T, Matsuzawa Y. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation. 2004; 109(17): 2046-9.
[124] Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun. 2004; 323(2): 630-5.
[125] Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun. 2004; 316(3): 924-9.
[126] Masaki T, Chiba S, Tatsukawa H, Yasuda T, Noguchi H, Seike M, Yoshimatsu H. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology. 2004; 40(1): 177-84.
[127] Wang W, Poole B, Mitra A, Falk S, Fantuzzi G, Lucia S, Schrier R. Role of leptin deficiency in early acute renal failure during endotoxemia in ob/ob mice. J Am Soc Nephrol. 2004; 15(3): 645-9.
[128] Kappes A, Loffler G. Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm Metab Res. 2000; 32(11-12): 548-54.
[129] Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T,Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003; 423(6941): 762-9.
[130] Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, Fukui K, Maeda N, Nishizawa H, Nagaretani H, Okamoto Y, Kihara S, Miyagawa J, Shinomura Y, Funahashi T, Matsuzawa Y. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology. 2003; 125(6): 1796-807.
[131] Petridou E, Mantzoros C, Dessypris N, Koukoulomatis P, Addy C, Voulgaris Z, Chrousos G, Trichopoulos D. Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab. 2003; 88(3): 993-7.
[132] Dal Maso L, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, Mantzoros CS, La Vecchia C. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab. 2004; 89(3): 1160-3.
[133] Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, Trichopoulos D. Adiponectin and breast cancer risk. J Clin Endocrinol Metab. 2004; 89(3): 1102-7.
[134] Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst. 2005; 97(22): 1688-94.
[135] Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Bioehem Biophys Res Commun. 2006; 340(4): 1158-66.
[136] Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol. 1991; 44(2): 139-43.
[137] Lucore CL, Fujii S, Wun TC, Sobel BE, Billadello JJ. Regulation of the expression of type 1 plasminogen activator inhibitor in Hep G2 cells by epidermal growth factor. J Biol Chem. 1988; 263(31): 15845-8.
[138] Lyon CJ, Hsueh WA. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med. 2003; 115(Suppl 8A): 62S-68S.
[139] Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1, lnt J Obes Relat Metab Disord. 2004; 28(11): 1357-64.
[140] Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost. 2003; 1(7): 1575-9.
[141] Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol. 1998; 18(1): 1-6.
[142] Morange PE, Alessi MC, Verdier M, Casanova D, Magalon G,Juhan-Vague I. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. Arterioscler Thromb Vasc Biol. 1999; 19(5): 1361-5.
[143] Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med. 1996; 2(7): 800-3.
[144] Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med. 1996; 2(5): 568-82.
[145] Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Helm M, Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients-relationship with plasma insulin. Thromb Haemost. 1989; 61(3): 370-3.
[146] Carmassi F, Morale M, Ferrini L, Dell'Omo G, Ferdeghini M, Pedrinelli R, De Negri F. Local insulin infusion stimulates expression of plasminogen activator inhibitor-1 and tissue-type plasminogen activator in normal subjects. Am J Med. 1999; 107(4): 344-50.
[147] Chen YQ, Su M, Walia RR, Hao Q, Covington JW, Vaughan DE. Spl sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem. 1998; 273(14): 8225-31.
[148] Panahloo A, Mohamed-Ali V, Andres C, Denver AE, Yudkin JS. Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes. Metabolism. 1998; 47(6): 637-43.
[149] Skurk T, Lee YM, Hauner H. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension. 2001; 37(5): 1336-40.
[150] Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension. 1999; 34(2): 285-90.
[151] Schafer K, Fujisawa K, Konstantinides S, Loskutoff DJ. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J. 2001; 15(10): 1840-2.
[152] Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH, Vaughan DE, Fogo AB. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes. 2004; 53(2): 336-46.
[153] Morange PE, Lijnen HR, Alessi MC, Kopp F, Collen D, Juhan-Vague I. Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol. 2000; 20(4): 1150-4.
[154] Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR.Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature. 1990; 346(6279): 74-6.
[155] Eren M, Painter CA, Atkinson JB, Declerck PJ, Vaughan DE. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation. 2002; 106(4): 491-6.
[156] Kruithof EK, Gudinchet A, Bachmann F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemost. 1988; 59(1): 7-12.
[157] Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987; 2(8549): 3-9.
[158] Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000; 342(24): 1792-801.
[159] Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med. 1992; 326(5): 310-8.
[160] Robbie LA, Booth NA, Brown AJ, Bennett B. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vase Biol. 1996; 16(4): 539-45.
[161] De Taeye B, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol. 2005; 5(2): 149-54.
[162] Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Janicke F, Meijer-van Gelder ME, Henzen-Logrnans SC, van Putten WL, Klijn JG The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 2000; 60(3): 636-43.
[163] Janicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost. 1991; 17(3): 303-12.
[164] Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F, Thomassen C, Look MP, Foekens JA. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer. 2004; 5(5): 348-52.
[165] Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001; 286(3): 327-34.
[166] Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, Paschke R. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2003; 301 (4): 1045-50.
[167] Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as anendocrine and paracrine organ, Int J Obes Relat Metab Disord. 1998; 22(12): 1145-58.
[168] Bruun JM, Helge JW, Richelsen B, Stallknecht B. Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am J Physiol Endocrinol Metab. 2006; 290(5): E961-7.
[169] Harkins JM, Moustaid-Moussa N, Chung YJ, Penner KM, Pestka JJ, North CM, Claycombe KJ. Expression of interleukin-6 is greater in preadipocytes than in adipocytes of 3T3-L1 ceils and C57BL/6J and ob/ob mice. J Nutr. 2004; 134(10): 2673-7.
[170] Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000; 148(2): 209-14.
[171] Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003; 111(12): 1805-12.
[172] Kritchevsky SB, Cesari M, Pahor M. Inflammatory markers and cardiovascular health in older adults. Cardiovasc Res. 2005; 66(2): 265-75.
[173] Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinoi Metab. 2000; 85(9): 3338-42.
[174] Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab. 2002; 87(5): 2084-9.
[175] Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes. 2002; 51(12): 3391-9.
[176] Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem. 2003; 278(16): 13740-6.
[177] Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc. 2001; 60(3): 349-56.
[178] Hotamisligil GS. Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord. 2000; 24(Suppl 4): S23-7.
[179] Moiler DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinoi Metab. 2000; 11 (6): 212-7.
[180] Ruan H, Miles PD, Ladd CM, Ross K, Golub TR, Olefsky JM, Lodish HF. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. Diabetes. 2002; 51(11): 3176-88.
[181] Wang P, Ba ZF, Chaudry IH. Administration of tumor necrosisfactor-alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol. 1994; 266(6 Pt 2): 2535-41.
[182] Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation. 1997; 96(9): 3042-7.
[183] Choy JC, Granville DJ, Hunt DW, McManus BM. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol. 2001; 33(9): 1673-90.
[184] Hermann C, Assmus B, Urbich C, Zeiher AM, Dimmeler S. Insulin-mediated stimulation of protein kinase Akt: A potent survival signaling cascade for endothelial cells. Arterioscler Thromb Vasc Biol. 2000; 20(2): 402-9.
[185] Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003; 107(5): 671-4.
[186] Mohamed-Aii V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997; 82(12): 4196-200.
[187] Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N. Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care. 2003; 26(10): 2754-7.
[188] Thorand B, Lowei H, Schneider A, Kolb H, Meisinger C, Frohlich M, Koenig W. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med. 2003; 163(1): 93-9.
[189] Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, Hoogeveen R, Folsom AR, Heiss G. Atherosclerosis Risk in Communities Study. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2003; 52(7): 1799-805.
[190] Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003; 107(3): 391-7.
[191] Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999; 282(22): 2131-5.
[192] Ford ES, Galuska DA, Gillespie C, Will JC, Giles WH, Dietz WH. C-reactive protein and body mass index in children: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. J Pediatr. 2001; 138(4): 486-92.
[193] Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Insulin ResistanceAtherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002; 51(4): 1131-7.
[194] Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ, Sattar N. West of Scotland Coronary Prevention Study. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002; 51(5): 1596-600.
[195] Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107(3): 363-9.
[196] Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000; 102(18): 2165-8.
[197] Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, Mickle DA. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002; 105(16): 1890-6.
[198] Verma S, Wang CH, Weisel RD, Badiwala MV, Li SH, Fedak PW, Li RK, Mickle DA. Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: reversal with rosiglitazone. J Mol Cell Cardiol. 2003; 35(4): 417-9.
[199] Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F. Effects of the obese gene product on body weight regulation in ob/ob mice. Science. 1995; 269(5223): 540-3.
[200] Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995; 269(5223): 543-6.
[201] Friedman 3M, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998 Oct 22; 395(6704): 763-70.
[202] Chua SC Jr, Chung WK, Wu-Peng XS, Zhang Y, Liu SM, Tartaglia L, Leibel RL. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science. 1996; 271(5251): 994-6.
[203] Chert H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell. 1996; 84(3): 491-5.
[204] Park HY, Kwon HM, Lim HJ, Hong BK, Lee JY, Park BE, Jang Y, Cho SY, Kim HS. Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med. 2001; 33(2): 95-102.
[205] Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ.Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest. 2001; 108(10): 1533-40.
[206] Cooke JP, Oka RK. Does leptin cause vascular disease? Circulation. 2002; 106(15): 1904-5.
[207] Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzman M, Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem. 2001; 276(27): 25096-100.
[208] Way JM, Gorgun CZ, Tong Q, Uysal KT, Brown KK, Harrington WW, Oliver WR Jr, Willson TM, Kliewer SA, Hotamisligil GS. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem. 2001; 276(28): 25651-3.
[209] Le Lay S, Boucher J, Rey A, Castan-Laurell I, Kfief S, Ferre P, Valet P, Dugail I. Decreased resistin expression in mice with different sensitivities to a high-fat diet. Biochem Biophys Res Commun. 2001; 289(2): 564-7.
[210] Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature. 2001; 409(6818): 307-12.
[211] Calabro P, Samudio I, Willerson JT, Yeh ET. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation. 2004; 110(21): 3335-40.
[212] Bruun JM, Pedersen SB, Richelsen B. Interleukin-8 production in human adipose tissue, inhibitory effects of anti-diabetic compounds, the thiazolidinedione ciglitazone and the biguanide metformin. Horm Metab Res. 2000; 32(11-12): 537-41.
[213] Bruun JM, Pedersen SB, Richelsen B. Regulation of interleukin 8 production and gene expression in human adipose tissue in vitro. J Clin Endocrinol Metab. 2001; 86(3): 1267-73.
[214] Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000; 21(6): 697-738.
[215] Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 2005; 288(5): H2031-41.
[216] Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vase Biol. 1999; 19(4): 972-8.
[217] Das UN. Is obesity an inflammatory condition? Nutrition. 2001; 17(11-12): 953-66.
[218] Festa A, D'Agostino R Jr, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, Haffner SM. The relation of body fat mass and distributionto markers of chronic inflammation, Int J Obes Relat Metab Disord. 2001; 25(10): 1407-15.
[219] Bullo M, Garcia-Lorda P, Megias I, Salas-Salvado J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res. 2003; 11(4): 525-31.
[220] Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005; 115(5): 1111-9.
[221] Hotamisligii GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord. 2003; 27(Suppl 3): S53-5.
[222] Yudkin JS. Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obes Relat Metab Disord. 2003; 27(Suppl 3): S25-8.
[223] Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112(12): 1796-808.
[224] Neels JG, Olefsky JM. Inflamed fat: what starts the fire? J Clin Invest. 2006; 116(1): 33-5.
[225] Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003; 112(12): 1821-30.
[226] Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004; 92(3): 347-55.
[227] Jansson PA, Larsson A, Smith U, Lonnroth P. Glycerol production in subcutaneous adipose tissue in lean and obese humans. J Clin Invest. 1992; 89(5): 1610-7.
[228] Virtanen KA, Lonnroth P, Parkkola R, Peltoniemi P, Asola M, Viljanen T, Tolvanen T, Knuuti J, Ronnemaa T, Huupponen R, Nuutila P. Glucose uptake and perfusion in subcutaneous and visceral adipose tissue during insulin stimulation in nonobese and obese humans. J Clin Endocrinol Metab. 2002; 87(8): 3902-10.
[229] Kabon B, Nagele A, Reddy D, Eagon C, Fleshman JW, Sessler DI, Kurz A. Obesity decreases perioperative tissue oxygenation. Anesthesiology. 2004; 100(2): 274-80.
[230] Rupnick MA, Panigrahy D, Zhang CY, Dallabrida SM, Lowell BB, Langer R, Folkman MJ. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A. 2002; 99(16): 10730-5.
[231] Lolmede K, Durand de Saint Front V, Galitzky J, Lafontan M, Bouloumie A. Int J Obes Relat Metab Disord. 2003; 27(10): 1187-95.
[232] Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002; 8(4 Suppl): S62-7.
[233] Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J. 2002; 16(10): 1151-62.
[234] Binley K, Askham Z, Martin L, Spearman H, Day D, Kingsman S, Naylor S. Hypoxia-mediated tumour targeting. Gene Ther.2003; 10(7): 540-9.
[235] Ambrosini G, Nath AK, Sierra-Honigmann MR, Flores-Riveros J. Transcriptional activation of the human leptin gene in response to hypoxia. Involvement of hypoxia-inducible factor 1. J Biol Chem. 2002; 277(37): 34601-9.
[236] Yamada N, Horikawa Y, Oda N, Iizuka K, Shihara N, Kishi S, Takeda J. Genetic variation in the hypoxia-inducible factor-1 alpha gene is associated with type 2 diabetes in Japanese. J Clin Endocrinol Metab. 2005; 90(10): 5841-7.
[237] Xu L, Pathak PS, Fukumura D. Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3'-kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells. Clin Cancer Res. 2004; 10(2): 701-7.
[238] Matsui H, Ihara Y, Fujio Y, Kunisada K, Akira S, Kishimoto T, Yamauchi-Takihara K. Induction of interleukin (IL)-6 by hypoxia is mediated by nuclear factor (NF)-kappa B and NF-IL6 in cardiac myocytes. Cardiovasc Res. 1999; 42(1): 104-12.
[239] Hagobian TA, Jacobs KA, Subudhi AW, Fattor JA, Rock PB, Muza SR, Fulco CS, Braun B, Grediagin A, Mazzeo RS, Cymerman A, Friedlander AL. Cytokine responses at high altitude: effects of exercise and antioxidants at 4300m. Med Sci Sports Exert. 2006; 38(2): 276-85.
[240] Kimura H. Increased expression of plasminogen activator inhibitor-1 in hypoxic renal injury and its pathological significance in progression of advanced renal disease. Rinsho Byori. 2005; 53(8): 749-58.
[241] Torii K, Kimura H, Li X, Okada T, Imura T, Furusaki F, Ono T, Yoshida H. Effects of hypoxia and tumor necrosis factor-alpha on production of plasminogen activator inhibitor-1 in human proximal renal tubular cells. Rinsho Byori. 2005; 53(3): 207-12.
[242] Garofalo C, Koda M, Cascio S, Sulkowska M, Kanezuga-Koda L, Golaszewska J, Russo A, Sulkowski S, Surmacz E. Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res. 2006; 12(5): 1447-53.
[243] Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006; 160(1): 1-40.
[244] Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem. 2004; 266(1-2): 37-56.
[245] Stadtman ER. Role of oxidant species in aging. Curr Med Chem. 2004; 11(9): 1105-12.
[246] Martin CJ, Goeddeke-Merickel CM. Oxidative stress in chronic kidney disease. Nephrol Nurs J. 2005; 32(6): 683-5.
[247] Chinopoulos C, Adam-Vizi V. Calcium, mitochondria and oxidative stress in neuronal pathology. Novel aspects of an enduring theme. FEBS J. 2006; 273(3): 433-50.
[248] Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414(6865): 813-20.
[249] Maddux BA, See W, Lawrence JC Jr, Goldfine AL, Goidfine ID, Evans JL. Protection against oxidative stress-induced insulin resistance in rat L6 muscle ceils by mircomolar concentrations of alpha-lipoic acid. Diabetes. 2001; 50(2): 404-10.
[250] Rudich A, Tirosh A, Potashnik R, Hemi R, Kanety H, Bashan N. Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes. 1998; 47( 10): 1562-9.
[251] Matsuoka T, Kajimoto Y, Watada H, Kaneto H, Kishimoto M, Umayahara Y, Fujitani Y, Kamada T, Kawamori R, Yamasaki Y. Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells. J Clin Invest. 1997; 99(1): 144-50.
[252] Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci U S A. 1991; 88(22): 10045-8.
[253] Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993; 91(6): 2546-51.
[254] Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004; 114(12): 1752-61.
[255] Fenster CP, Weinsier RL, Darley-Usmar VM, Patel RP. Obesity, aerobic exercise, and vascular disease: the role of oxidant stress. Obes Res. 2002; 10(9): 964-8.
[256] Koruk M, Taysi S, Savas MC, Yilmaz O, Akcay F, Karakok M. Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. Ann Clin Lab Sci. 2004; 34(1): 57-62.
[257] Steffes MW, Gross MD, Lee DH, Schreiner PJ, Jacobs DR Jr. Adiponectin, visceral fat, oxidative stress, and early macrovascular disease: the coronary artery risk development in young adults study. Obes Res. 2006; 14(2): 319-26.
[258] Kamigaki M, Sakaue S, Tsujino I, Ohira H, Ikeda D, Itoh N, lshimaru S, Ohtsuka Y, Nishimura M. Oxidative stress provokes atherogenic changes in adipokine gene expression in 3T3-LI adipocytes. Biochem Biophys Res Commun. 2006; 339(2): 624-32.
[259] Wang B, Jenkins JR, Trayhurn P. Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-alpha. Am J Physiol Endocrinol Metab. 2005; 288(4): E731-40.
[260] Thakur V, Pritchard MT, McMullen MR, Nagy LE. Adiponectin normalizes LPS-stimulated TNF-{alpha} production by rat Kupffer cells after chronic ethanol feeding. Am J Physiol Gastrointest Liver Physiol. 2006; 290(5): G998-G1007.
[261] Saijo S, Nagata K, Nakano Y, Tobe T, Kobayashi Y. Inhibition by adiponectin of IL-8 production by human macrophages upon coculturing with late apoptotic cells. Biochem Biophys Res Commun. 2005; 334(4): 1180-3.
[262] Ailhaud G, Grimaldi P, Negrel R. Cellular and molecular aspects of adipose tissue development. Annu Rev Nutr. 1992; 12: 207-33.
[263] Wang Y, Xu A, Knight C, Xu LY, Cooper GJ. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J Biol Chem. 2002; 277(22): 19521-9.
[264] Xu A, Yin S, Wong L, Chan KW, Lam KS. Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrinology. 2004; 145(2): 487-94.
[265] Brahimi-Horn C, Mazure N, Pouyssegur J. Signalling via the hypoxia-inducible factor-lalpha requires multiple posttranslational modifications. Cell Signal. 2005; 17(1): 1-9.
[266] Ockaili R, Natarajan R, Salloum F, Fisher BJ, Jones D, Fowler AA 3rd, Kukreja RC. HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation. Am J Physiol Heart Circ Physiol. 2005; 289(2): H542-8.
[267] Soares AF, Guichardant M, Cozzone D, Bemoud-Hubac N, Bouzaidi-Tiali N, Lagarde M, Geloen A. Effects of oxidative stress on adiponectin secretion and lactate production in 3T3-L1 adipocytes. Free Radio Biol Med. 2005; 38(7): 882-9.
[268] Sato H, Sato M, Kanai H, Uchiyama T, Iso T, Ohyama Y, Sakamoto H, Tamura J, Nagai R, Kurabayashi M. Mitochondrial reactive oxygen species and c-Src play a critical role in hypoxic response in vascular smooth muscle cells. Cardiovasc Res. 2005; 67(4): 714-22.
[269] Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, Schumacker PT. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci U S A. 1998; 95(20): 11715-20.
[270] Park SK, Oh SY, Lee MY, Yoon S, Kim KS, Kim JW. CCAAT/enhancer binding protein and nuclear factor-Y regulate adiponectin gene expression in adipose tissue. Diabetes. 2004; 53(11): 2757-66.
[271] Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes. 2003; 52(7): 1655-63.
[272] Zirlik A, Leugers A, Lohrmann J, Ernst S, Sobel BE, Bode C, Nordt TK. Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones. Thromb Haemost. 2004; 91(4): 674-82.
[273] Fleischmann E, Kurz A, Niedermayr M, Schebesta K, Kimberger O,Sessler DI, Kabon B, Prager G. Tissue oxygenation in obese and non-obese patients during laparoscopy. Obes Surg. 2005; 15(6): 813-9.
[274] Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, Coupaye M, Pelloux V, Hugol D, Bouillot JL, Bouloumie A, Barbatelli G, Cinti S, Svensson PA, Barsh GS, Zucker JD, Basdevant A, Langin D, Clement K. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes. 2005; 54(8): 2277-86.
[275] Kietzmann T, Roth U, Jungermann K. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood. 1999; 94(12): 4177-85.
[276] Kietzmann T, Samoylenko A, Roth U, Jungermann K. Hypoxia-inducible factor-1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes. Blood. 2003; 101 (3): 907-14.
[277] Qiao L, Maclean PS, Schaack J, Orlicky DJ, Darimont C, Pagliassotti M, Friedman JE, Shao J. C/EBPalpha regulates human adiponectin gene transcription through an intronic enhancer. Diabetes. 2005; 54(6): 1744-54.
[278] Kietzmann T, Gorlach A. Reactive oxygen species in the control of hypoxia-indueible factor-mediated gene expression. Semin Cell Dev Biol. 2005; 16(4-5): 474-86.
[279] Archer SL, Huang J, Henry T, Peterson D, Weir EK. A redox-based O2 sensor in rat pulmonary vasculature. Circ Res. 1993; 73(6): 1100-12.
[280] Michelakis ED, Hampl V, Nsair A, Wu X, Harry G, Haromy A, Gurtu R, Archer SL. Diversity in mitochondrial function explains differences in vascular oxygen sensing. Circ Res. 2002; 90(12): 1307-15.
[281] Hool LC, Arthur PG. Decreasing cellular hydrogen peroxide with catalase mimics the effects of hypoxia on the sensitivity of the L-type Ca~(2+) channel to beta-adrenergic receptor stimulation in cardiac myocytes. Circ Res. 2002; 91 (7): 601-9.
[282] Marshall C, Mamary AJ, Verhoeven AJ, Marshall BE. Pulmonary artery NADPH-oxidase is activated in hypoxic pulmonary vasoconstriction. Am J Respir Cell Mol Biol. 1996; 15(5): 633-44.
[283] Gorlach A, Diebold I, Schini-Kerth VB, Berchner-Pfannschmidt U, Roth U, Brandes RP, Kietzmann T, Busse R. Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: Role of the p22(phox)-containing NADPH oxidase. Circ Res. 2001; 89(1): 47-54.
[284] Uchiyama T, Engelman RM, Maulik N, Das DK. Role of Akt signaling in mitochondrial survival pathway triggered by hypoxic preconditioning. Circulation. 2004; 109(24): 3042-9.
[285] Clerk A, Michael A, Sugden PH. Stimulation of multiple mitogen-activated protein kinase sub-families by oxidative stress andphosphorylation of the small heat shock protein, HSP25/27, in neonatal ventricular myocytes. Biochem J. 1998; 333(Pt3): 581-9.
[286] Zhou Y, Wang Q, Evers BM, Chung DH. Signal transduction pathways involved in oxidative stress-induced intestinal epithelial cell apoptosis. Pediatr Res. 2005; 58(6): 1192-7.
[287] Shaw M, Cohen P, Alessi DR. The activation of protein kinase B by H_2O_2 or heat shock is mediated by phosphoinositide 3-kinase and not by mitogen-activated protein kinase-activated protein kinase-2. Biochem J. 1998; 336(Pt 1): 241-6.
[288] Carballo M, Conde M, El Bekay R, Martin-Nieto J, Camacho M J, Monteseirin J, Conde J, Bedoya FJ, Sobrino F. Oxidative stress triggers STAT3 tyrosine phosphorylation and nuclear transloeation in human lymphocytes. J Biol Chem. 1999; 274(25): 17580-6.
[289] Madamanchi NR, Li S, Patterson C, Runge MS. Reactive oxygen species regulate heat-shock protein 70 via the JAK/STAT pathway. Arterioscler Thromb Vase Biol. 2001; 21(3): 321-6.
[290] Simon AR, Rai U, Fanburg BL, Cochran BH. Activation of the JAK-STAT pathway by reactive oxygen species. Am J Physiol. 1998; 275(6Pt 1): C1640-52.
[291] Zima T, Kalousova M. Oxidative stress and signal transduction pathways in alcoholic liver disease. Alcohol Clin Exp Res. 2005; 29(11 Suppl): 110S-115S.
[292] Masamune A, Kikuta K, Satoh M, Satoh A, Shimosegawa T. Alcohol activates activator protein-1 and mitogen-activated protein kinases in rat pancreatic stellate cells. J Pharmacol Exp Ther. 2002; 302(1): 36-42.
[293] Kyriakis JM, Avruch J. Sounding the alarm: protein kinase cascades activated by stress and inflammation. J Biol Chem. 1996; 271(40): 24313-6.
[294] Callsen D, Brune B. Role of mitogen-activated protein kinases in S-nitrosoglutathione-induced macrophage apoptosis. Biochemistry. 1999; 38(8): 2279-86.
[295] Fujita Y, Izawa Y, Ali N, Kanematsu Y, Tsuchiya K, Hamano S, Tamaki T, Yoshizumi M. Pramipexole protects against H(2)O(2)-induced PC12 cell death. Naunyn Schmiedebergs Arch Pharmacol. 2006; 372(4): 257-66.
[296] Lawlor MA, Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci. 2001; 114(Pt 16): 2903-10.
[297] Wang X, McCullough KD, Franke TF, Holbrook NJ. Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival. J Biol Chem. 2000; 275(19): 14624-31.
[298] Tu VC, Bahl JJ, Chen QM. Signals of oxidant-induced cardiomyocyte hypertrophy: key activation of p70 S6 kinase-1 and phosphoinositide 3-kinase. J Pharmacol Exp Ther. 2002; 300(3): 1101-10.
[299] Chen F, Castranova V, Shi X. New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol. 2001; 159(2): 387-97.
[300] Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997; 336( 15): 1066-71.
[301] Valen G, Yan ZQ, Hansson GK. Nuclear factor kappa-B and the heart. J Am Coll Cardiol. 2001; 38(2): 307-14.
[302] Gupta S, Sen S. Role of the NF-kappaB signaling cascade and NF-kappaB-targeted genes in failing human hearts. J Mol Med. 2005; 83(12): 993-1004.
[303] Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 1991; 10(8): 2247-58.
[304] Byun MS, Jeon KI, Choi JW, Shim JY, Jue DM. Dual effect of oxidative stress on NF-kappakB activation in HeLa cells. Exp Mol Med. 2002; 34(5): 332-9.
[305] Meyer M, Schreck R, Baeuerle PA. H_2O_2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J. 1993; 12(5): 2005-15.
[306] Mehlen P, Kretz-Remy C, Preville X, Arrigo AP. Human hsp27, Drosophila hsp27 and human alphaB-crystallin expression-mediated increase in glutathione is essential for the protective activity of these proteins against TNFalpha-induced cell death. EMBO J. 1996; 15(11): 2695-706.
[307] Manna SK, Zhang HJ, Yan T, Oberley LW, Aggarwal BB. Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappaB and activated protein-1. J Biol Chem. 1998; 273(21): 13245-54.
[308] Kim H, Kim YN, Kim H, Kim CW. Oxidative stress attenuates Fas-mediated apoptosis in Jurkat T cell line through Bfl-1 induction. Oncogene. 2005; 24(7): 1252-61.
[309] Takacs P, Kauma SW, Shoiley MM, Walsh SW, Dinsmoor MJ, Green K. Increased circulating lipid peroxides in severe preeclampsia activate NF-kappaB and upregulate ICAM-1 in vascular endothelial cells. FASEB J. 2001; 15(2): 279-81.
[2] Gallagher D, Visser M, Sepulveda D, Pierson RN, Harris T, Heymsfield SB. How useful is body mass index for comparison of body fatness across age, sex, and ethnic groups? Am J Epidemiol. 1996; 143(3): 228-39.
[3] Kopelman PG Obesity as a medical problem. Nature. 2000; 404(6778): 635-43.
[4] WHO. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Consultation. World Health Organ Tech Rep Ser. 1995; 854: 1-452.
[5] WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363(9403): 157-63.
[6] Eckel RH, York DA, Rossner S, Hubbard V, Caterson I, St Jeor ST, Hayman LL, Mullis RM, Blair SN. American Heart Association. Prevention Conference VII: Obesity, a worldwide epidemic related to heart disease and stroke: executive summary. Circulation. 2004; 110(18): 2968-75.
[7] Seidell JC. Prevalence and time trends of obesity in Europe. J Endocrinol Invest. 2002; 25(10): 816-22.
[8] Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA. 2004; 291 (23): 2847-50.
[9] Li G, Chen X, Jang Y, Wang J, Xing X, Yang W, Hu Y. Obesity, coronary heart disease risk factors and diabetes in Chinese: an approach to the criteria of obesity in the Chinese population. Obes Rev. 2002; 3(3): 167-72.
[10] Schwarzenberg SJ. Obesity in children: epidemic and opportunity. Minn Med. 2005; 88(9): 62-6.
[11] Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, Grummer-Strawn LM, Curtin LR, Roche AF, Johnson CL. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics. 2002; 109(1): 45-60.
[12] Magarey AM, Daniels LA, Boulton TJ. Prevalence of overweight and obesity in Australian children and adolescents: reassessment of 1985 and 1995 data against new standard international definitions. Med J Aust. 2001; 174(11): 561-4.
[13] Lobstein T, Baur L, Uauy R. IASO International Obesity TaskForce. Obesity in children and young people: a crisis in public health. Obes Rev. 2004;5(Suppl 1): 4-104.
[14] James PT, Leach R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. Obes Res. 2001; 9(Suppl 4): 228S-233S.
[15] Kohn M, Booth M. The worldwide epidemic of obesity in adolescents. Adolesc Med. 2003; 14(1): 1-9.
[16] Krassas GE, Tzotzas T. Do obese children become obese adults: childhood predictors of adult disease. Pediatr Endocrinol Rev. 2004; 1( Suppl 3): 455-9.
[17] Haslam DW, James WP. Obesity. Lancet. 2005; 366(9492): 1197-209.
[18] James WPT, Jackson-Leach R, Ni Mhurchu C. Overweight and obesity (high body mass index). In: Ezzati M, Lopez AD, Rodgers A, Murray CJL, eds. Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors, vol 1. Geneva: WHO, 2004: 497-596.
[19] Strohl KP, Strobel RJ, Parisi RA. Obesity and pulmonary function. In: Bray GA, Bouchard C, James WP, eds. Handbook of obesity: etiology and pathophysiology. 2nd. New York, Marcel Dekker; 2004: 725-739.
[20] Felson DT, Anderson JJ, Naimark A, Walker AM, Meenan RF. Obesity and knee osteoarthritis. The Framingham Study. Ann Intern Med. 1988; 109(1): 18-24.
[21] Chan JM, Rimm EB, Colditz GA, Stampfer MJ, Willett WC. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care. 1994; 17(9): 961-9.
[22] Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 1995; 122(7): 481-6.
[23] Seidell JC, Verschuren WM, van Leer EM, Kromhout D. Overweight, underweight, and mortality. A prospective study of 48, 287 men and women. Arch Intern Med. 1996; 156(9): 958-63.
[24] Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH. American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006; 113(6): 898-918.
[25] Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patients. Gastroenterology. 2000; 118(6): 1117-23.
[26] Ko CW, Lee SP. Dietary carbohydrates and gallstones: is there a link? Gastroenterology. 2005; 129(1): 373-5.
[27] Lew EA. Mortality and weight: insured lives and the American Cancer Society studies. Ann Intern Med. 1985; 103(6 (Pt 2)): 1024-9.
[28] Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE. Body weight and mortality among women. N Engl J Med. 1995; 333(11): 677-85.
[29] Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. JAMA. 2003; 289(2): 187-93.
[30] Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J, Hayflick L, Butler RN, Allison DB, Ludwig DS. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005; 352(11): 1138-45.
[31] Peeters A, Barendregt JJ, Willekens F, Mackenbach JP, AI Mamun A, Bonneux L. NEDCOM, the Netherlands Epidemiology and Demography Compression of Morbidity Research Group. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med. 2003; 138(1): 24-32.
[32] Hu FB, Willett WC, Li T, Stampfer MJ, Colditz GA, Manson JE. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med. 2004; 351(26): 2694-703.
[33] Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983; 67(5): 968-77.
[34] Eckei RH. Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1997; 96(9): 3248-50.
[35] Willett WC, Manson JE, Stampfer MJ, Colditz GA, Rosner B, Speizer FE, Hennekens CH. Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range. JAMA. 1995; 273(6): 461-5.
[36] Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, Willett WC. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol. 1995; 141 (12): 1117-27.
[37] Alpert MA. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci. 2001; 321(4): 225-36.
[38] Kasper EK, Hruban RH, Baughman KL. Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. Am J Cardiol. 1992; 70(9): 921-4.
[39] Mattsson E, Larsson UE, Rossner S. Is walking for exercise too exhausting for obese women? Int J Obes Relat Metab Disord. 1997; 21(5): 380-6.
[40] Poirier P, Despres JP. Exercise in weight management of obesity. Cardiol Ciin. 2001; 19(3): 459-70.
[41] Messerli FH. Cardiopathy of obesity-a not-so-Victorian disease. N Engl J Med. 1986; 314(6): 378-80.
[42] Ku CS, Lin SL, Wang DJ, Chang SK, Lee WJ. Left ventricular filling in young normotensive obese adults. Am J Cardiol. 1994; 73(8): 613-5.
[43] Alpert MA, Lambert CR, Panayiotou H, Terry BE, Cohen MV, Massey CV, Hashimi MW, Mukerji V. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. Am J Cardiol. 1995; 76(16): 1194-7.
[44] Cheyne J. A case of apoplexy in which the fleshy part of the heart wasconverted into fat. Dublin Hosp Rep. 1818; 2: 216-223.
[45] Smith HL, Willius FA. Adiposity of the heart: a clinical and pathologic study of one hundred and thirty-six obese patients. Arch Intern Med. 1933; 52: 911-931.
[46] Roberts WC, Roberts JD. The floating heart or the heart too fat to sink: analysis of 55 necropsy patients. Am J Cardiol. 1983; 52(10): 1286-9.
[47] Carpenter HM. Myocardial fat infiltration. Am Heart J. 1962;63:491-6.
[48] Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A. 2000; 97(4): 1784-9.
[49] Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS. Obesity and the risk of heart failure. N Engl J Med. 2002; 347(5): 305-13.
[50] Klein S, Burke LE, Bray GA, Blair S, Allison DB, Pi-Sunyer X, Hong Y, Eckel RH. American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2004; 110(18): 2952-67.
[51] Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med. 2002; 162(10): 1182-9.
[52] McGill HC Jr, McMahan CA, Herderick EE, Zieske AW, Malcom GT, Tracy RE, Strong JP. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation. 2002; 105(23): 2712-8.
[53] Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. A prospective study of risk factors for pulmonary embolism in women. JAMA. 1997; 277(8): 642-5.
[54] Blaszyk H, Wollan PC, Witkiewicz AK, Bjornsson J. Death from pulmonary thromboembolism in severe obesity: lack of association with established genetic and clinical risk factors. Virchows Arch. 1999; 434(6): 529-32.
[55] Blaszyk H, Bjornsson J. Factor V leiden and morbid obesity in fatal postoperative pulmonary embolism. Arch Surg. 2000; 135(12): 1410-3.
[56] Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA. 1978; 240(15): 1607-10.
[57] Arcaro G, Zamboni M, Rossi L, Turcato E, Covi G, Armellini F, Bosello O, Lechi A. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity, Int J Obes RelatMetab Disord. 1999; 23(9): 936-42.
[58] Lee KU. Oxidative stress markers in Korean subjects with insulin resistance syndrome. Diabetes Res Clin Pract. 2001; 54(Suppl 2): S29-33.
[59] Amin RS, Kimball TR, Bean JA, Jeffries JL, Willging JP, Cotton RT, Witt SA, Glascock BJ, Daniels SR. Left ventricular hypertrophy and abnormal ventricular geometry in children and adolescents with obstructive sleep apnea. Am J Respir Crit Care Med. 2002; 165(10): 1395-9.
[60] Brown DL. Sleep disorders and stroke. Semin Neurol. 2006; 26(1): 117-22.
[61] Dursunoglu N, Dursunoglu D. Obstructive sleep apnea syndrome, endothelial dysfunction and coronary atherosclerosis. Tuberk Toraks. 2005; 53(3): 299-306.
[62] Hale CS. Obstructive sleep apnea and cardiovascular disease and mortality: the argument for causality. J Insur Med. 2005; 37(4): 272-82.
[63] Guerra S, Sherrill DL, Bobadilla A, Martinez FD, Barbee RA. The relation of body mass index to asthma, chronic bronchitis, and emphysema. Chest. 2002; 122(4): 1256-63.
[64] Gennuso J, Epstein LH, Paluch RA, Cerny F. The relationship between asthma and obesity in urban minority children and adolescents. Arch Pediatr Adolesc Med. 1998; 152(12): 1197-200.
[65] Schachter LM, Salome CM, Peat JK, Woolcock AJ. Obesity is a risk for asthma and wheeze but not airway hyperresponsiveness. Thorax. 2001; 56(1): 4-8.
[66] Schachter LM, Peat JK, Salome CM. Asthma and atopy in overweight children. Thorax. 2003; 58(12): 1031-5.
[67] Bibi H, Shoseyov D, Feigenbaum D, Genis M, Friger M, Peled R, Sharff S. The relationship between asthma and obesity in children: is it real or a case of over diagnosis? J Asthma. 2004; 41(4): 403-10.
[68] Sims EA, Danforth E Jr, Horton ES, Bray GA, Glennon JA, Salans LB. Endocrine and metabolic effects of experimental obesity in man. Recent Prog Horm Res. 1973; 29: 457-96.
[69] Bray GA. Risks of obesity. Endocrinol Metab Clin North Am. 2003; 32(4): 787-804.
[70] Stevens J, Couper D, Pankow J, Folsom AR, Duncan BB, Nieto FJ, Jones D, Tyroler HA. Sensitivity and specificity of anthropometrics for the prediction of diabetes in a biracial cohort. Obes Res. 2001; 9(11): 696-705.
[71] Pinhas-Hamiel O, Dolan LM, Daniels SR, Standiford D, Khoury PR, Zeitler P. Increased incidence of non-insulin-dependent diabetes mellitus among adolescents. J Pediatr. 1996; 128(5 Pt 1): 608-15.
[72] Pinkney JH, Sjostrom CD, Gale EA. Should surgeons treat diabetes in severely obese people? Lancet. 2001; 357(9265): 1357-9.
[73] Golay A, Ybarra J. Link between obesity and type 2 diabetes. Best Pract Res Clin Endocrinol Metab. 2005; 19(4): 649-63.
[74] Tilg H, Kaser A. Treatment strategies in nonalcoholic fatty liver disease. Nat Clin Pratt Gastroenterol Hepatol. 2005; 2(3): 148-55.
[75] Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol. 2005; 16(4): 421-7.
[76] Santoliquido A, Di Campli C, Miele L, Gabrieli ML, Forgione A, Zocco MA, Lupascu A, Di Giorgio A, Flore R, Pola P, Gasbarrini G, Gasbarrini A, Tondi P, Grieco A. Hepatic steatosis and vascular disease. Eur Rev Med Pharmacol Sci. 2005; 9(5): 269-71.
[77] Marra F, Aleffi S, Bertolani C, Petrai I, Vizzutti F. Adipokines and liver fibrosis. Eur Rev Med Pharmacol Sci. 2005 Sep-Oct; 9(5): 279-84.
[78] Clark JM, Brancati FL, Diehi AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002; 122(6): 1649-57.
[79] Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology. 2002; 35(4): 746-52.
[80] Wieckowska A, Feldstein AE. Nonalcoholic fatty liver disease in the pediatric population: a review. Curr Opin Pediatr. 2005; 17(5): 636-41.
[81] Clark JM. Weight loss as a treatment for nonalcoholic Fatty liver disease. J Clin Gastroenterol. 2006; 40(Suppl 1): S39-43.
[82] Bugianesi E. Review article: steatosis, the metabolic syndrome and cancer. Aliment Pharmacol Ther. 2005; (22 Suppl 2): 40-3.
[83] Stolzenberg-Solomon RZ, Graubard BI, Chari S, Limburg P, Taylor PR, Virtamo J, Albanes D. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA. 2005; 294(22): 2872-8.
[84] Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005; 143(3): 199-211.
[85] Hou L, Ji BT, Blair A, Dai Q, Gao YT, Potter JD, Chow WH. Body mass index and colon cancer risk in Chinese people: menopause as an effect modifier. Eur J Cancer. 2006; 42(1): 84-90.
[86] Frezza EE, Wachtel MS, Chiriva-Internati M. Influence of obesity on the risk of developing colon cancer. Gut. 2006; 55(2): 285-91.
[87] Fairfield KM, Willett WC, Rosner BA, Manson JE, Speizer FE, Hankinson SE. Obesity, weight gain, and ovarian cancer. Obstet Gynecol. 2002; 100(2): 288-96.
[88] Sonne-Holm S, Jacobsen S. Osteoarthritis and obesity. Ugeskr Laeger. 2006; 168(2): 187-90.
[89] Leveille SG, Wee CC, Iezzoni LI. Trends in obesity and arthritis among baby boomers and their predecessors, 1971-2002. Am J Public Health. 2005; 95(9): 1607-13.
[90] Gross AF, Fickert S, Gunther KP. Obesity and arthritis. Orthopade. 2005; 34(7): 638-44.
[91] Christensen R, Stigsgaard L, Astrup AV, Bliddal H. Weight loss as therapy of knee osteoarthritis in obese patients-secondary publication. Ugeskr Laeger. 2005; 167(23): 2522-6.
[92] Messier SP, Gutekunst DJ, Davis C, DeVita P. Weight loss reducesknee-joint loads in overweight and obese older adults with knee osteoarthritis. Arthritis Rheum. 2005; 52(7): 2026-32.
[93] Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med. 2003; 163(13): 1524-8.
[94] de Leeuw FE, van der Flier WM, Scheltens P. A 24-year follow-up of body mass index and cerebral atrophy. Neurology. 2005; 64(11): 1990-1;
[95] Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004; 3(3): 169-78.
[96] Green BB, Weiss NS, Daling JR. Risk of ovulatory infertility in relation to body weight. Fertii Steril. 1988; 50(5): 721-6.
[97] Esposito K, Giugliano F, Di Palo C, Giugliano G, Marfella R, D'Andrea F, D'Armiento M, Giugliano D. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. 2004; 291(24): 2978-84.
[98] Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab. 2004; 89(6): 2595-600.
[99] Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005; 115(5): 911-9.
[100] Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes Metab. 2004; 30(1): 13-9.
[101] Trujillo ME, Scherer PE. Adiponectin--journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005; 257(2): 167-75.
[102] Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, Matsuzawa Y. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes. 2001; 50(5): 1126-33.
[103] Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 2002; 360(9326): 57-8.
[104] Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H, Kumada M, Ohashi K, Okamoto Y, Nishizawa H, Kishida K, Maeda N, Nagasawa A, Kobayashi H, Hiraoka H, Komai N, Kaibe M, Rakugi H, Ogihara T, Matsuzawa Y. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension. 2003; 42(3): 231-4.
[105] Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, Dabelea D, Hokanson JE, Ehrlich J, Eckel RH, Rewers M. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation. 2005; 111(6): 747-53.
[106] Lam KS, Xu A. Adiponectin: protection of the endothelium. Curt Diab Rep. 2005; 5(4): 254-9.
[107] Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M,Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002; 8(7): 731-7.
[108] Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, Eto K, Yamashita T, Kamon J, Satoh H, Yano W, Froguel P, Nagai R, Kimura S, Kadowaki T, Noda T. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem. 2002; 277(29): 25863-6.
[109] Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR, Kumada M, Sato K, Schiekofer S, Ohashi K, Funahashi T, Colucci WS, Walsh K. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med. 2004; 10(12): 1384-9.
[110] Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, Ohashi K, Sakai N, Shimomura I, Kobayashi H, Terasaka N, Inaba T, Funahashi T, Matsuzawa Y. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2002; 106(22): 2767-70.
[111] Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003; 112(1): 91-100.
[112] Tsao TS, Lodish HF, Fruebis J. ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol. 2002; 440(2-3): 213-21.
[113] Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab. 2002; 13(2): 84-9.
[114] Patel C, Wyne KL, MeGuire DK. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? Diab Vase Dis Res. 2005; 2(2): 61-6.
[115] Hetzel J, Balletshofer B, Rittig K, Walcher D, Kratzer W, Hombaeh V, Haring HU, Koenig W, Marx N. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vase Biol. 2005; 25(9): 1804-9.
[116] Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002; 8(11): 1288-95.
[117] Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang Cc C, Itani SI, Lodish HF, Ruderman NB. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A. 2002; 99(25): 16309-13.
[118] Combs TP, Berg AH, Obici S, Scherer PE, Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest. 2001; 108(12): 1875-81.
[119] Wu X, Motoshima H, Mahadev K, Stalker TJ, Scalia R, Goldstein BJ. Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes. 2003; 52(6): 1355-63.
[120] Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation. 2000; 102(11): 1296-301.
[121] Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999; 100(25): 2473-6.
[122] Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, Kumada M, Hotta K, Nishida M, Takahashi M, Nakamura T, Shimomura I, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation. 2002; 105(24): 2893-8.
[123] Kumada M, Kihara S, Ouchi N, Kobayashi H, Okamoto Y, Ohashi K, Maeda K, Nagaretani H, Kishida K, Maeda N, Nagasawa A, Funahashi T, Matsuzawa Y. Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation. 2004; 109(17): 2046-9.
[124] Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun. 2004; 323(2): 630-5.
[125] Wulster-Radcliffe MC, Ajuwon KM, Wang J, Christian JA, Spurlock ME. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun. 2004; 316(3): 924-9.
[126] Masaki T, Chiba S, Tatsukawa H, Yasuda T, Noguchi H, Seike M, Yoshimatsu H. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology. 2004; 40(1): 177-84.
[127] Wang W, Poole B, Mitra A, Falk S, Fantuzzi G, Lucia S, Schrier R. Role of leptin deficiency in early acute renal failure during endotoxemia in ob/ob mice. J Am Soc Nephrol. 2004; 15(3): 645-9.
[128] Kappes A, Loffler G. Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes. Horm Metab Res. 2000; 32(11-12): 548-54.
[129] Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T,Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003; 423(6941): 762-9.
[130] Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, Fukui K, Maeda N, Nishizawa H, Nagaretani H, Okamoto Y, Kihara S, Miyagawa J, Shinomura Y, Funahashi T, Matsuzawa Y. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology. 2003; 125(6): 1796-807.
[131] Petridou E, Mantzoros C, Dessypris N, Koukoulomatis P, Addy C, Voulgaris Z, Chrousos G, Trichopoulos D. Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab. 2003; 88(3): 993-7.
[132] Dal Maso L, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, Mantzoros CS, La Vecchia C. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab. 2004; 89(3): 1160-3.
[133] Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, Trichopoulos D. Adiponectin and breast cancer risk. J Clin Endocrinol Metab. 2004; 89(3): 1102-7.
[134] Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst. 2005; 97(22): 1688-94.
[135] Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Bioehem Biophys Res Commun. 2006; 340(4): 1158-66.
[136] Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol. 1991; 44(2): 139-43.
[137] Lucore CL, Fujii S, Wun TC, Sobel BE, Billadello JJ. Regulation of the expression of type 1 plasminogen activator inhibitor in Hep G2 cells by epidermal growth factor. J Biol Chem. 1988; 263(31): 15845-8.
[138] Lyon CJ, Hsueh WA. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med. 2003; 115(Suppl 8A): 62S-68S.
[139] Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1, lnt J Obes Relat Metab Disord. 2004; 28(11): 1357-64.
[140] Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost. 2003; 1(7): 1575-9.
[141] Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol. 1998; 18(1): 1-6.
[142] Morange PE, Alessi MC, Verdier M, Casanova D, Magalon G,Juhan-Vague I. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. Arterioscler Thromb Vasc Biol. 1999; 19(5): 1361-5.
[143] Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med. 1996; 2(7): 800-3.
[144] Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med. 1996; 2(5): 568-82.
[145] Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Helm M, Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients-relationship with plasma insulin. Thromb Haemost. 1989; 61(3): 370-3.
[146] Carmassi F, Morale M, Ferrini L, Dell'Omo G, Ferdeghini M, Pedrinelli R, De Negri F. Local insulin infusion stimulates expression of plasminogen activator inhibitor-1 and tissue-type plasminogen activator in normal subjects. Am J Med. 1999; 107(4): 344-50.
[147] Chen YQ, Su M, Walia RR, Hao Q, Covington JW, Vaughan DE. Spl sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem. 1998; 273(14): 8225-31.
[148] Panahloo A, Mohamed-Ali V, Andres C, Denver AE, Yudkin JS. Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes. Metabolism. 1998; 47(6): 637-43.
[149] Skurk T, Lee YM, Hauner H. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension. 2001; 37(5): 1336-40.
[150] Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension. 1999; 34(2): 285-90.
[151] Schafer K, Fujisawa K, Konstantinides S, Loskutoff DJ. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J. 2001; 15(10): 1840-2.
[152] Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH, Vaughan DE, Fogo AB. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes. 2004; 53(2): 336-46.
[153] Morange PE, Lijnen HR, Alessi MC, Kopp F, Collen D, Juhan-Vague I. Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler Thromb Vasc Biol. 2000; 20(4): 1150-4.
[154] Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR.Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature. 1990; 346(6279): 74-6.
[155] Eren M, Painter CA, Atkinson JB, Declerck PJ, Vaughan DE. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation. 2002; 106(4): 491-6.
[156] Kruithof EK, Gudinchet A, Bachmann F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemost. 1988; 59(1): 7-12.
[157] Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987; 2(8549): 3-9.
[158] Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000; 342(24): 1792-801.
[159] Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med. 1992; 326(5): 310-8.
[160] Robbie LA, Booth NA, Brown AJ, Bennett B. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vase Biol. 1996; 16(4): 539-45.
[161] De Taeye B, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol. 2005; 5(2): 149-54.
[162] Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Janicke F, Meijer-van Gelder ME, Henzen-Logrnans SC, van Putten WL, Klijn JG The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 2000; 60(3): 636-43.
[163] Janicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemost. 1991; 17(3): 303-12.
[164] Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F, Thomassen C, Look MP, Foekens JA. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer. 2004; 5(5): 348-52.
[165] Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001; 286(3): 327-34.
[166] Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J, Paschke R. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun. 2003; 301 (4): 1045-50.
[167] Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as anendocrine and paracrine organ, Int J Obes Relat Metab Disord. 1998; 22(12): 1145-58.
[168] Bruun JM, Helge JW, Richelsen B, Stallknecht B. Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am J Physiol Endocrinol Metab. 2006; 290(5): E961-7.
[169] Harkins JM, Moustaid-Moussa N, Chung YJ, Penner KM, Pestka JJ, North CM, Claycombe KJ. Expression of interleukin-6 is greater in preadipocytes than in adipocytes of 3T3-L1 ceils and C57BL/6J and ob/ob mice. J Nutr. 2004; 134(10): 2673-7.
[170] Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000; 148(2): 209-14.
[171] Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003; 111(12): 1805-12.
[172] Kritchevsky SB, Cesari M, Pahor M. Inflammatory markers and cardiovascular health in older adults. Cardiovasc Res. 2005; 66(2): 265-75.
[173] Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinoi Metab. 2000; 85(9): 3338-42.
[174] Bastard JP, Maachi M, Van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab. 2002; 87(5): 2084-9.
[175] Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes. 2002; 51(12): 3391-9.
[176] Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem. 2003; 278(16): 13740-6.
[177] Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc. 2001; 60(3): 349-56.
[178] Hotamisligil GS. Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord. 2000; 24(Suppl 4): S23-7.
[179] Moiler DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinoi Metab. 2000; 11 (6): 212-7.
[180] Ruan H, Miles PD, Ladd CM, Ross K, Golub TR, Olefsky JM, Lodish HF. Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. Diabetes. 2002; 51(11): 3176-88.
[181] Wang P, Ba ZF, Chaudry IH. Administration of tumor necrosisfactor-alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol. 1994; 266(6 Pt 2): 2535-41.
[182] Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation. 1997; 96(9): 3042-7.
[183] Choy JC, Granville DJ, Hunt DW, McManus BM. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol. 2001; 33(9): 1673-90.
[184] Hermann C, Assmus B, Urbich C, Zeiher AM, Dimmeler S. Insulin-mediated stimulation of protein kinase Akt: A potent survival signaling cascade for endothelial cells. Arterioscler Thromb Vasc Biol. 2000; 20(2): 402-9.
[185] Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003; 107(5): 671-4.
[186] Mohamed-Aii V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997; 82(12): 4196-200.
[187] Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N. Elevated C-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care. 2003; 26(10): 2754-7.
[188] Thorand B, Lowei H, Schneider A, Kolb H, Meisinger C, Frohlich M, Koenig W. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med. 2003; 163(1): 93-9.
[189] Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, Hoogeveen R, Folsom AR, Heiss G. Atherosclerosis Risk in Communities Study. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2003; 52(7): 1799-805.
[190] Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003; 107(3): 391-7.
[191] Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999; 282(22): 2131-5.
[192] Ford ES, Galuska DA, Gillespie C, Will JC, Giles WH, Dietz WH. C-reactive protein and body mass index in children: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. J Pediatr. 2001; 138(4): 486-92.
[193] Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Insulin ResistanceAtherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002; 51(4): 1131-7.
[194] Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, O'Reilly DS, Packard CJ, Sattar N. West of Scotland Coronary Prevention Study. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002; 51(5): 1596-600.
[195] Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003; 107(3): 363-9.
[196] Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000; 102(18): 2165-8.
[197] Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, Mickle DA. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002; 105(16): 1890-6.
[198] Verma S, Wang CH, Weisel RD, Badiwala MV, Li SH, Fedak PW, Li RK, Mickle DA. Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: reversal with rosiglitazone. J Mol Cell Cardiol. 2003; 35(4): 417-9.
[199] Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F. Effects of the obese gene product on body weight regulation in ob/ob mice. Science. 1995; 269(5223): 540-3.
[200] Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995; 269(5223): 543-6.
[201] Friedman 3M, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998 Oct 22; 395(6704): 763-70.
[202] Chua SC Jr, Chung WK, Wu-Peng XS, Zhang Y, Liu SM, Tartaglia L, Leibel RL. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science. 1996; 271(5251): 994-6.
[203] Chert H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell. 1996; 84(3): 491-5.
[204] Park HY, Kwon HM, Lim HJ, Hong BK, Lee JY, Park BE, Jang Y, Cho SY, Kim HS. Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med. 2001; 33(2): 95-102.
[205] Konstantinides S, Schafer K, Koschnick S, Loskutoff DJ.Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest. 2001; 108(10): 1533-40.
[206] Cooke JP, Oka RK. Does leptin cause vascular disease? Circulation. 2002; 106(15): 1904-5.
[207] Yamagishi SI, Edelstein D, Du XL, Kaneda Y, Guzman M, Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem. 2001; 276(27): 25096-100.
[208] Way JM, Gorgun CZ, Tong Q, Uysal KT, Brown KK, Harrington WW, Oliver WR Jr, Willson TM, Kliewer SA, Hotamisligil GS. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem. 2001; 276(28): 25651-3.
[209] Le Lay S, Boucher J, Rey A, Castan-Laurell I, Kfief S, Ferre P, Valet P, Dugail I. Decreased resistin expression in mice with different sensitivities to a high-fat diet. Biochem Biophys Res Commun. 2001; 289(2): 564-7.
[210] Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature. 2001; 409(6818): 307-12.
[211] Calabro P, Samudio I, Willerson JT, Yeh ET. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation. 2004; 110(21): 3335-40.
[212] Bruun JM, Pedersen SB, Richelsen B. Interleukin-8 production in human adipose tissue, inhibitory effects of anti-diabetic compounds, the thiazolidinedione ciglitazone and the biguanide metformin. Horm Metab Res. 2000; 32(11-12): 537-41.
[213] Bruun JM, Pedersen SB, Richelsen B. Regulation of interleukin 8 production and gene expression in human adipose tissue in vitro. J Clin Endocrinol Metab. 2001; 86(3): 1267-73.
[214] Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000; 21(6): 697-738.
[215] Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 2005; 288(5): H2031-41.
[216] Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vase Biol. 1999; 19(4): 972-8.
[217] Das UN. Is obesity an inflammatory condition? Nutrition. 2001; 17(11-12): 953-66.
[218] Festa A, D'Agostino R Jr, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, Haffner SM. The relation of body fat mass and distributionto markers of chronic inflammation, Int J Obes Relat Metab Disord. 2001; 25(10): 1407-15.
[219] Bullo M, Garcia-Lorda P, Megias I, Salas-Salvado J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res. 2003; 11(4): 525-31.
[220] Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005; 115(5): 1111-9.
[221] Hotamisligii GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord. 2003; 27(Suppl 3): S53-5.
[222] Yudkin JS. Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obes Relat Metab Disord. 2003; 27(Suppl 3): S25-8.
[223] Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112(12): 1796-808.
[224] Neels JG, Olefsky JM. Inflamed fat: what starts the fire? J Clin Invest. 2006; 116(1): 33-5.
[225] Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003; 112(12): 1821-30.
[226] Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004; 92(3): 347-55.
[227] Jansson PA, Larsson A, Smith U, Lonnroth P. Glycerol production in subcutaneous adipose tissue in lean and obese humans. J Clin Invest. 1992; 89(5): 1610-7.
[228] Virtanen KA, Lonnroth P, Parkkola R, Peltoniemi P, Asola M, Viljanen T, Tolvanen T, Knuuti J, Ronnemaa T, Huupponen R, Nuutila P. Glucose uptake and perfusion in subcutaneous and visceral adipose tissue during insulin stimulation in nonobese and obese humans. J Clin Endocrinol Metab. 2002; 87(8): 3902-10.
[229] Kabon B, Nagele A, Reddy D, Eagon C, Fleshman JW, Sessler DI, Kurz A. Obesity decreases perioperative tissue oxygenation. Anesthesiology. 2004; 100(2): 274-80.
[230] Rupnick MA, Panigrahy D, Zhang CY, Dallabrida SM, Lowell BB, Langer R, Folkman MJ. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci U S A. 2002; 99(16): 10730-5.
[231] Lolmede K, Durand de Saint Front V, Galitzky J, Lafontan M, Bouloumie A. Int J Obes Relat Metab Disord. 2003; 27(10): 1187-95.
[232] Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002; 8(4 Suppl): S62-7.
[233] Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J. 2002; 16(10): 1151-62.
[234] Binley K, Askham Z, Martin L, Spearman H, Day D, Kingsman S, Naylor S. Hypoxia-mediated tumour targeting. Gene Ther.2003; 10(7): 540-9.
[235] Ambrosini G, Nath AK, Sierra-Honigmann MR, Flores-Riveros J. Transcriptional activation of the human leptin gene in response to hypoxia. Involvement of hypoxia-inducible factor 1. J Biol Chem. 2002; 277(37): 34601-9.
[236] Yamada N, Horikawa Y, Oda N, Iizuka K, Shihara N, Kishi S, Takeda J. Genetic variation in the hypoxia-inducible factor-1 alpha gene is associated with type 2 diabetes in Japanese. J Clin Endocrinol Metab. 2005; 90(10): 5841-7.
[237] Xu L, Pathak PS, Fukumura D. Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3'-kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells. Clin Cancer Res. 2004; 10(2): 701-7.
[238] Matsui H, Ihara Y, Fujio Y, Kunisada K, Akira S, Kishimoto T, Yamauchi-Takihara K. Induction of interleukin (IL)-6 by hypoxia is mediated by nuclear factor (NF)-kappa B and NF-IL6 in cardiac myocytes. Cardiovasc Res. 1999; 42(1): 104-12.
[239] Hagobian TA, Jacobs KA, Subudhi AW, Fattor JA, Rock PB, Muza SR, Fulco CS, Braun B, Grediagin A, Mazzeo RS, Cymerman A, Friedlander AL. Cytokine responses at high altitude: effects of exercise and antioxidants at 4300m. Med Sci Sports Exert. 2006; 38(2): 276-85.
[240] Kimura H. Increased expression of plasminogen activator inhibitor-1 in hypoxic renal injury and its pathological significance in progression of advanced renal disease. Rinsho Byori. 2005; 53(8): 749-58.
[241] Torii K, Kimura H, Li X, Okada T, Imura T, Furusaki F, Ono T, Yoshida H. Effects of hypoxia and tumor necrosis factor-alpha on production of plasminogen activator inhibitor-1 in human proximal renal tubular cells. Rinsho Byori. 2005; 53(3): 207-12.
[242] Garofalo C, Koda M, Cascio S, Sulkowska M, Kanezuga-Koda L, Golaszewska J, Russo A, Sulkowski S, Surmacz E. Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. Clin Cancer Res. 2006; 12(5): 1447-53.
[243] Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006; 160(1): 1-40.
[244] Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem. 2004; 266(1-2): 37-56.
[245] Stadtman ER. Role of oxidant species in aging. Curr Med Chem. 2004; 11(9): 1105-12.
[246] Martin CJ, Goeddeke-Merickel CM. Oxidative stress in chronic kidney disease. Nephrol Nurs J. 2005; 32(6): 683-5.
[247] Chinopoulos C, Adam-Vizi V. Calcium, mitochondria and oxidative stress in neuronal pathology. Novel aspects of an enduring theme. FEBS J. 2006; 273(3): 433-50.
[248] Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001; 414(6865): 813-20.
[249] Maddux BA, See W, Lawrence JC Jr, Goldfine AL, Goidfine ID, Evans JL. Protection against oxidative stress-induced insulin resistance in rat L6 muscle ceils by mircomolar concentrations of alpha-lipoic acid. Diabetes. 2001; 50(2): 404-10.
[250] Rudich A, Tirosh A, Potashnik R, Hemi R, Kanety H, Bashan N. Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes. 1998; 47( 10): 1562-9.
[251] Matsuoka T, Kajimoto Y, Watada H, Kaneto H, Kishimoto M, Umayahara Y, Fujitani Y, Kamada T, Kawamori R, Yamasaki Y. Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells. J Clin Invest. 1997; 99(1): 144-50.
[252] Nakazono K, Watanabe N, Matsuno K, Sasaki J, Sato T, Inoue M. Does superoxide underlie the pathogenesis of hypertension? Proc Natl Acad Sci U S A. 1991; 88(22): 10045-8.
[253] Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993; 91(6): 2546-51.
[254] Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004; 114(12): 1752-61.
[255] Fenster CP, Weinsier RL, Darley-Usmar VM, Patel RP. Obesity, aerobic exercise, and vascular disease: the role of oxidant stress. Obes Res. 2002; 10(9): 964-8.
[256] Koruk M, Taysi S, Savas MC, Yilmaz O, Akcay F, Karakok M. Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. Ann Clin Lab Sci. 2004; 34(1): 57-62.
[257] Steffes MW, Gross MD, Lee DH, Schreiner PJ, Jacobs DR Jr. Adiponectin, visceral fat, oxidative stress, and early macrovascular disease: the coronary artery risk development in young adults study. Obes Res. 2006; 14(2): 319-26.
[258] Kamigaki M, Sakaue S, Tsujino I, Ohira H, Ikeda D, Itoh N, lshimaru S, Ohtsuka Y, Nishimura M. Oxidative stress provokes atherogenic changes in adipokine gene expression in 3T3-LI adipocytes. Biochem Biophys Res Commun. 2006; 339(2): 624-32.
[259] Wang B, Jenkins JR, Trayhurn P. Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-alpha. Am J Physiol Endocrinol Metab. 2005; 288(4): E731-40.
[260] Thakur V, Pritchard MT, McMullen MR, Nagy LE. Adiponectin normalizes LPS-stimulated TNF-{alpha} production by rat Kupffer cells after chronic ethanol feeding. Am J Physiol Gastrointest Liver Physiol. 2006; 290(5): G998-G1007.
[261] Saijo S, Nagata K, Nakano Y, Tobe T, Kobayashi Y. Inhibition by adiponectin of IL-8 production by human macrophages upon coculturing with late apoptotic cells. Biochem Biophys Res Commun. 2005; 334(4): 1180-3.
[262] Ailhaud G, Grimaldi P, Negrel R. Cellular and molecular aspects of adipose tissue development. Annu Rev Nutr. 1992; 12: 207-33.
[263] Wang Y, Xu A, Knight C, Xu LY, Cooper GJ. Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J Biol Chem. 2002; 277(22): 19521-9.
[264] Xu A, Yin S, Wong L, Chan KW, Lam KS. Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrinology. 2004; 145(2): 487-94.
[265] Brahimi-Horn C, Mazure N, Pouyssegur J. Signalling via the hypoxia-inducible factor-lalpha requires multiple posttranslational modifications. Cell Signal. 2005; 17(1): 1-9.
[266] Ockaili R, Natarajan R, Salloum F, Fisher BJ, Jones D, Fowler AA 3rd, Kukreja RC. HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation. Am J Physiol Heart Circ Physiol. 2005; 289(2): H542-8.
[267] Soares AF, Guichardant M, Cozzone D, Bemoud-Hubac N, Bouzaidi-Tiali N, Lagarde M, Geloen A. Effects of oxidative stress on adiponectin secretion and lactate production in 3T3-L1 adipocytes. Free Radio Biol Med. 2005; 38(7): 882-9.
[268] Sato H, Sato M, Kanai H, Uchiyama T, Iso T, Ohyama Y, Sakamoto H, Tamura J, Nagai R, Kurabayashi M. Mitochondrial reactive oxygen species and c-Src play a critical role in hypoxic response in vascular smooth muscle cells. Cardiovasc Res. 2005; 67(4): 714-22.
[269] Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, Schumacker PT. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci U S A. 1998; 95(20): 11715-20.
[270] Park SK, Oh SY, Lee MY, Yoon S, Kim KS, Kim JW. CCAAT/enhancer binding protein and nuclear factor-Y regulate adiponectin gene expression in adipose tissue. Diabetes. 2004; 53(11): 2757-66.
[271] Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes. 2003; 52(7): 1655-63.
[272] Zirlik A, Leugers A, Lohrmann J, Ernst S, Sobel BE, Bode C, Nordt TK. Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones. Thromb Haemost. 2004; 91(4): 674-82.
[273] Fleischmann E, Kurz A, Niedermayr M, Schebesta K, Kimberger O,Sessler DI, Kabon B, Prager G. Tissue oxygenation in obese and non-obese patients during laparoscopy. Obes Surg. 2005; 15(6): 813-9.
[274] Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, Coupaye M, Pelloux V, Hugol D, Bouillot JL, Bouloumie A, Barbatelli G, Cinti S, Svensson PA, Barsh GS, Zucker JD, Basdevant A, Langin D, Clement K. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes. 2005; 54(8): 2277-86.
[275] Kietzmann T, Roth U, Jungermann K. Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. Blood. 1999; 94(12): 4177-85.
[276] Kietzmann T, Samoylenko A, Roth U, Jungermann K. Hypoxia-inducible factor-1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes. Blood. 2003; 101 (3): 907-14.
[277] Qiao L, Maclean PS, Schaack J, Orlicky DJ, Darimont C, Pagliassotti M, Friedman JE, Shao J. C/EBPalpha regulates human adiponectin gene transcription through an intronic enhancer. Diabetes. 2005; 54(6): 1744-54.
[278] Kietzmann T, Gorlach A. Reactive oxygen species in the control of hypoxia-indueible factor-mediated gene expression. Semin Cell Dev Biol. 2005; 16(4-5): 474-86.
[279] Archer SL, Huang J, Henry T, Peterson D, Weir EK. A redox-based O2 sensor in rat pulmonary vasculature. Circ Res. 1993; 73(6): 1100-12.
[280] Michelakis ED, Hampl V, Nsair A, Wu X, Harry G, Haromy A, Gurtu R, Archer SL. Diversity in mitochondrial function explains differences in vascular oxygen sensing. Circ Res. 2002; 90(12): 1307-15.
[281] Hool LC, Arthur PG. Decreasing cellular hydrogen peroxide with catalase mimics the effects of hypoxia on the sensitivity of the L-type Ca~(2+) channel to beta-adrenergic receptor stimulation in cardiac myocytes. Circ Res. 2002; 91 (7): 601-9.
[282] Marshall C, Mamary AJ, Verhoeven AJ, Marshall BE. Pulmonary artery NADPH-oxidase is activated in hypoxic pulmonary vasoconstriction. Am J Respir Cell Mol Biol. 1996; 15(5): 633-44.
[283] Gorlach A, Diebold I, Schini-Kerth VB, Berchner-Pfannschmidt U, Roth U, Brandes RP, Kietzmann T, Busse R. Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: Role of the p22(phox)-containing NADPH oxidase. Circ Res. 2001; 89(1): 47-54.
[284] Uchiyama T, Engelman RM, Maulik N, Das DK. Role of Akt signaling in mitochondrial survival pathway triggered by hypoxic preconditioning. Circulation. 2004; 109(24): 3042-9.
[285] Clerk A, Michael A, Sugden PH. Stimulation of multiple mitogen-activated protein kinase sub-families by oxidative stress andphosphorylation of the small heat shock protein, HSP25/27, in neonatal ventricular myocytes. Biochem J. 1998; 333(Pt3): 581-9.
[286] Zhou Y, Wang Q, Evers BM, Chung DH. Signal transduction pathways involved in oxidative stress-induced intestinal epithelial cell apoptosis. Pediatr Res. 2005; 58(6): 1192-7.
[287] Shaw M, Cohen P, Alessi DR. The activation of protein kinase B by H_2O_2 or heat shock is mediated by phosphoinositide 3-kinase and not by mitogen-activated protein kinase-activated protein kinase-2. Biochem J. 1998; 336(Pt 1): 241-6.
[288] Carballo M, Conde M, El Bekay R, Martin-Nieto J, Camacho M J, Monteseirin J, Conde J, Bedoya FJ, Sobrino F. Oxidative stress triggers STAT3 tyrosine phosphorylation and nuclear transloeation in human lymphocytes. J Biol Chem. 1999; 274(25): 17580-6.
[289] Madamanchi NR, Li S, Patterson C, Runge MS. Reactive oxygen species regulate heat-shock protein 70 via the JAK/STAT pathway. Arterioscler Thromb Vase Biol. 2001; 21(3): 321-6.
[290] Simon AR, Rai U, Fanburg BL, Cochran BH. Activation of the JAK-STAT pathway by reactive oxygen species. Am J Physiol. 1998; 275(6Pt 1): C1640-52.
[291] Zima T, Kalousova M. Oxidative stress and signal transduction pathways in alcoholic liver disease. Alcohol Clin Exp Res. 2005; 29(11 Suppl): 110S-115S.
[292] Masamune A, Kikuta K, Satoh M, Satoh A, Shimosegawa T. Alcohol activates activator protein-1 and mitogen-activated protein kinases in rat pancreatic stellate cells. J Pharmacol Exp Ther. 2002; 302(1): 36-42.
[293] Kyriakis JM, Avruch J. Sounding the alarm: protein kinase cascades activated by stress and inflammation. J Biol Chem. 1996; 271(40): 24313-6.
[294] Callsen D, Brune B. Role of mitogen-activated protein kinases in S-nitrosoglutathione-induced macrophage apoptosis. Biochemistry. 1999; 38(8): 2279-86.
[295] Fujita Y, Izawa Y, Ali N, Kanematsu Y, Tsuchiya K, Hamano S, Tamaki T, Yoshizumi M. Pramipexole protects against H(2)O(2)-induced PC12 cell death. Naunyn Schmiedebergs Arch Pharmacol. 2006; 372(4): 257-66.
[296] Lawlor MA, Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci. 2001; 114(Pt 16): 2903-10.
[297] Wang X, McCullough KD, Franke TF, Holbrook NJ. Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival. J Biol Chem. 2000; 275(19): 14624-31.
[298] Tu VC, Bahl JJ, Chen QM. Signals of oxidant-induced cardiomyocyte hypertrophy: key activation of p70 S6 kinase-1 and phosphoinositide 3-kinase. J Pharmacol Exp Ther. 2002; 300(3): 1101-10.
[299] Chen F, Castranova V, Shi X. New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol. 2001; 159(2): 387-97.
[300] Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997; 336( 15): 1066-71.
[301] Valen G, Yan ZQ, Hansson GK. Nuclear factor kappa-B and the heart. J Am Coll Cardiol. 2001; 38(2): 307-14.
[302] Gupta S, Sen S. Role of the NF-kappaB signaling cascade and NF-kappaB-targeted genes in failing human hearts. J Mol Med. 2005; 83(12): 993-1004.
[303] Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 1991; 10(8): 2247-58.
[304] Byun MS, Jeon KI, Choi JW, Shim JY, Jue DM. Dual effect of oxidative stress on NF-kappakB activation in HeLa cells. Exp Mol Med. 2002; 34(5): 332-9.
[305] Meyer M, Schreck R, Baeuerle PA. H_2O_2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J. 1993; 12(5): 2005-15.
[306] Mehlen P, Kretz-Remy C, Preville X, Arrigo AP. Human hsp27, Drosophila hsp27 and human alphaB-crystallin expression-mediated increase in glutathione is essential for the protective activity of these proteins against TNFalpha-induced cell death. EMBO J. 1996; 15(11): 2695-706.
[307] Manna SK, Zhang HJ, Yan T, Oberley LW, Aggarwal BB. Overexpression of manganese superoxide dismutase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappaB and activated protein-1. J Biol Chem. 1998; 273(21): 13245-54.
[308] Kim H, Kim YN, Kim H, Kim CW. Oxidative stress attenuates Fas-mediated apoptosis in Jurkat T cell line through Bfl-1 induction. Oncogene. 2005; 24(7): 1252-61.
[309] Takacs P, Kauma SW, Shoiley MM, Walsh SW, Dinsmoor MJ, Green K. Increased circulating lipid peroxides in severe preeclampsia activate NF-kappaB and upregulate ICAM-1 in vascular endothelial cells. FASEB J. 2001; 15(2): 279-81.